Andrew Gin, MD
Neurology · Oklahoma City, OKNPI 1336110717
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,633 and has fallen 78.7% since, to $349 in 2025.
Across 319 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$643
- Kyowa Kirin, Inc.$516
- UCB, Inc.$437
- Amgen$349
- Supernus Pharmaceuticals, Inc.$303
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$431%
- Food & beverage$5,83999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,303 |
| Neurocrine Biosciences, Inc. | 29 | $643 |
| Kyowa Kirin, Inc. | 27 | $516 |
| UCB, Inc. | 23 | $437 |
| Amgen | 16 | $349 |
| Supernus Pharmaceuticals, Inc. | 22 | $303 |
| Sunovion Pharmaceuticals Inc. | 20 | $298 |
| Acadia Pharmaceuticals Inc | 12 | $297 |
| Amneal Pharmaceuticals LLC | 6 | $192 |
| Lilly USA, LLC | 15 | $190 |
| Pfizer | 8 | $150 |
| Eisai Inc. | 8 | $135 |
| Acorda Therapeutics, Inc | 7 | $131 |
| Corium, LLC | 5 | $94 |
| SK Life Science, Inc. | 5 | $92 |
| Avion Pharmaceuticals | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $71 |
| Novartis | 4 | $67 |
| Biohaven Pharmaceuticals, Inc. | 5 | $62 |
| Adamas Pharmaceuticals, Inc. | 3 | $52 |
| Neurelis, Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Upsher-smith Laboratories LLC | 2 | $36 |
| Lundbeck LLC | 2 | $35 |
| GE HealthCare | 1 | $30 |
| Zyla Life Sciences, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Abbott | 1 | $25 |
| Biogen | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Argenx US, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,882 in reported general payments places this provider in the 65th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 21 | $27,064 |
| Nurtec OdtRimegepant Sulfate | 20 | $26,464 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $11,493 |
| BriviactBrivaracetam | 11 | $8,703 |
| OngentysOpicapone | 13 | $8,416 |
| DilantinPhenytoin Sodium Extended | 25 | $7,299 |
| Entacapone | 63 | $5,483 |
| Lacosamide | 18 | $2,035 |
| Memantine Hcl | 80 | $2,033 |
| Rivastigmine | 15 | $1,797 |
| Donepezil Hcl | 248 | $1,650 |
| Levetiracetam | 82 | $1,609 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 82 | $1,524 |
| Gabapentin | 38 | $940 |
| Primidone | 29 | $778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Dilantin | $150 | $33,76345 claims |
| AbbVieBotox | $1,303 | $27,06421 claims |
| UCB, Inc.Briviact | $437 | $8,70311 claims |
| Neurocrine Biosciences, Inc.Ongentys | $643 | $8,41613 claims |
| Upsher-smith Laboratories LLCTopiramate | $36 | $13516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 152 neurology providers in Oklahoma.
Other neurology in Oklahoma City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Mariana VargaOklahoma City$183K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$158K
- Christi PendergraftOklahoma City$73K
- Courtney IserOklahoma City$56K
- Jeanne KingOklahoma City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.